Healthcare and Life Science
Sphere Fluidics awarded Gold accreditation by Investors in People
Internationally-recognized ‘We invest in people’ award is certified recognition of the Company’s care and commitment to its employees globally ...
Animating the science of a firearm - WaveFX
WaveFX writes...our talented CG artists can bring any process to life, for example this STEM based client wanted to show the firing process of a firearm as part of a series of educational videos. ...
Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker
Low doses of ETD001 demonstrate exceptionally long duration of action in sheep model of airway mucus clearance Report in Journal of Cystic Fibrosis discloses best-in-class profile of ETD001 ETD001 scheduled to commence Phase 2 clinical study in people with cystic fibrosis in summe...
Newcells Biotech strengthens executive and US team with key appointments
Dr Valeria Chichagova appointed as Director of Technology, Dr Colin Brown as Chief Scientific Officer, and Professor Lyle Armstrong as Scientific Advisor New US commercial appointments also announced to meet growing global demand for products and services Newcastle, UK - New...
Cambridge-based Cofinitive Communications recognised amongst international PR and Communications industry elite
Cambridge-based PR & Comms agency, Cofinitive Communications has been listed in PR Week’s Top 150 PR agency rankings for a third consecutive year. ...
I do not live with diabetes – should I be monitoring my glucose with CGM?
Nowadays, CGMs are being promoted by various biotech companies and social media influencers as tools for understanding and improving health. Unfortunately, I can see a rise in poorly evidenced health messages. In addition, there are many misleading ads risking people’s health. More in ...
Nuclera awarded £1.14M Innovate UK funding for development of eProtein Discovery
£790k FASST grant, in collaboration with DeepMirror, and £350k Engineering Biology grant awarded for platform development. ...
MediMab Biotherapeutics opens bespoke laboratory facilities, created by Kadans Science Partner, at Abingdon Science Park, UK
New CL2 wet lab purpose-built facilities delivered by Kadans Science Partner will support MediMab Biotherapeutics to identify first-in-class immuno-oncology drugs that can actively target a range of advanced and solid tumours Kadans has also completed on Barton House, a new research...
Time from EMA approval to CT outcome for first indication vs. AMSR
This post launches a series of infographics focused on pricing and market access trends of rare disease treatments in France. Each post in this series zooms into a specific PMA trend by leveraging RADAR, CRA’s orphan drug data repository that includes all orphan drugs granted EMA approv...
Impact of medicare price “negotiation” program on small and large molecule medicines
The Inflation Reduction Act (IRA) directs the U.S. federal government to set a “Maximum Fair Price” (MFP) for the medicines with the highest spending in Medicare. The MFP will be implemented for selected small molecule drugs as early as nine years after approval, and as early as 13 year...